When we treated prostate cancer cells which do not express endogenous NPY (DU145, LNCaP and PC3) with recombinant NPY (48 h, 25 nM), we observed greater glucose uptake in NPY-treated cells than in untreated cells (Figure 5C). This evidence concerns the gene NPY and prostate cancer.